Brokerages expect Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to announce $0.05 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Enanta Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.13 and the lowest estimate coming in at ($0.04). Enanta Pharmaceuticals posted earnings of ($0.26) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 119.2%. The business is scheduled to issue its next earnings results on Wednesday, February 14th.

According to Zacks, analysts expect that Enanta Pharmaceuticals will report full-year earnings of ($1.57) per share for the current fiscal year, with EPS estimates ranging from ($2.36) to ($0.78). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Enanta Pharmaceuticals.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, November 20th. The biotechnology company reported $1.86 EPS for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a return on equity of 6.46% and a net margin of 17.23%. The company had revenue of $75.93 million for the quarter, compared to the consensus estimate of $73.80 million. During the same quarter last year, the business earned ($0.09) EPS. Enanta Pharmaceuticals’s revenue was up 491.3% on a year-over-year basis.

A number of brokerages have weighed in on ENTA. JMP Securities raised their target price on Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. Royal Bank of Canada downgraded Enanta Pharmaceuticals from an “outperform” rating to a “sector perform” rating and set a $54.00 target price on the stock. in a report on Tuesday, January 2nd. Zacks Investment Research downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Finally, TheStreet raised Enanta Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Wednesday, December 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Enanta Pharmaceuticals currently has an average rating of “Hold” and an average price target of $45.25.

Several hedge funds have recently modified their holdings of the business. SG Americas Securities LLC boosted its holdings in shares of Enanta Pharmaceuticals by 5.8% in the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 237 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Enanta Pharmaceuticals by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 53,616 shares of the biotechnology company’s stock valued at $1,930,000 after purchasing an additional 304 shares in the last quarter. Thrivent Financial For Lutherans boosted its holdings in shares of Enanta Pharmaceuticals by 7.3% in the 2nd quarter. Thrivent Financial For Lutherans now owns 8,410 shares of the biotechnology company’s stock valued at $303,000 after purchasing an additional 570 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in shares of Enanta Pharmaceuticals by 7.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 12,787 shares of the biotechnology company’s stock valued at $460,000 after purchasing an additional 933 shares in the last quarter. Finally, Voya Investment Management LLC boosted its holdings in shares of Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Voya Investment Management LLC now owns 8,350 shares of the biotechnology company’s stock valued at $300,000 after purchasing an additional 977 shares in the last quarter. 66.83% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Enanta Pharmaceuticals (NASDAQ ENTA) traded up $1.78 during mid-day trading on Tuesday, hitting $62.76. The company’s stock had a trading volume of 188,310 shares, compared to its average volume of 143,670. The firm has a market cap of $1,166.30, a P/E ratio of 71.32 and a beta of 0.64. Enanta Pharmaceuticals has a 52-week low of $25.92 and a 52-week high of $63.08.

COPYRIGHT VIOLATION NOTICE: “Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of $0.05 Per Share” was first posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/16/enanta-pharmaceuticals-inc-enta-expected-to-announce-earnings-of-0-05-per-share.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.